The landscape of heart rhythm management is transforming, driven by rapid advancements in electrophysiology (EP) and cutting-edge technologies. In this edition of The Numbers, we take a closer look at key developments in the field and explore some of the most exciting companies pushing the boundaries of heart rhythm disorder treatment.
Heart rhythm disorders, also known as arrhythmias, affect millions of people worldwide. Over the past few decades, the treatment of these disorders has undergone a dramatic shift. The introduction of various technologies, including AI-powered tools, advanced imaging systems, and minimally invasive treatments, has significantly improved outcomes for patients.
Historically, the management of heart rhythm disorders relied heavily on devices like pacemakers and implantable cardioverter-defibrillators (ICDs). Today, we’re seeing the rise of new solutions, such as non-invasive treatments, AI-driven monitoring, and advanced imaging, each offering unique benefits to both patients and physicians.
With the industry moving rapidly forward, the future of heart rhythm management looks increasingly bright. In this article, we will dive into some of the most innovative players in the space and explore the trends that are driving this fast-growing sector.
The heart rhythm management market continues to see steady growth, driven by an increasing prevalence of arrhythmias and innovations in treatment options. According to LSI’s recently updated Global Surgical Procedure Volumes (SPV) database, heart rhythm management procedures, including ablation procedures, are projected to experience significant growth in the coming years.
In 2024, approximately 1.4 million cardiac ablation procedures were performed globally. Over the next five years, the volume of heart rhythm management procedures is expected to rise sharply, driven by the growing prevalence of heart conditions, the adoption of new technologies, and an aging population.
The market for mapping & ablation consoles & catheters, which support these procedures, is projected to see a growth rate of 9.3% CAGR from 2024 to 2029, according to LSI’s Compass solution. This indicates a significant opportunity for medtech companies to capitalize on the expanding market for heart rhythm management devices and procedures.
As the cardiac rhythm management devices market expands, several emerging companies are standing out for their innovative approaches. These companies are not just introducing new products; they are shaping the future of electrophysiology by leveraging advanced technologies such as AI, robotics, and non-invasive treatments. Here are some of the most notable players:
Company |
CEO |
Stage |
Raised to Date |
AccurKardia |
Juan C. Jimenez |
Seed |
$3.2M |
CAIRDAC |
Edouard Fonck |
Series A |
~$18.5M |
CardiaCare |
Amir Soltanianzadeh |
Series A |
$4.5M |
EBAMed |
Marina Izzo |
Series A |
~$22.0M |
Volta Medical |
Théophile Mohr Durdez |
Series B |
~$69.0M |
AccurKardia is revolutionizing the way heart rhythm disorders are diagnosed. The company’s FDA-cleared AccurECG platform uses artificial intelligence to provide faster, more accurate diagnoses of arrhythmias across a range of disorders. Its device-agnostic platform supports remote patient monitoring and ambulatory outpatient care, significantly improving efficiency for clinicians and patient outcomes.
Cairdac is taking a novel approach to heart rhythm management with its self-sustaining, leadless pacemaker. The ALPS system is powered by the heart’s kinetic energy and utilizes predictive algorithms to optimize energy usage, extending the longevity of the device. This innovative pacemaker eliminates the need for leads and reduces the need for battery replacements, offering a groundbreaking solution for patients requiring long-term pacing support.
CardiaCare’s wearable system offers a non-invasive approach to atrial fibrillation (AFib) treatment. The closed-loop neuromodulation system provides personalized electrical stimulation to the Median-Vagus axis, aiming to reduce AFib symptoms and improve the quality of life for patients. With over 60 million people globally living with AFib, this technology represents a significant shift towards non-invasive treatment options in the heart rhythm management space.
EBAMed is pioneering a non-invasive method for treating heart arrhythmias. By combining synchronized ultrasound imaging with proton beam therapy, EBAMed is developing a system that can ablate arrhythmic foci without the need for catheters. This groundbreaking approach could expand treatment options for patients and offer a viable alternative to traditional invasive treatments.
Volta Medical is leveraging AI to enhance electrophysiology procedures. Its AI-powered software, Volta AF-Xplorer, helps electrophysiologists identify and target complex arrhythmias by analyzing dispersed electrograms during ablation. By providing real-time guidance, Volta’s solution improves ablation outcomes and has the potential to revolutionize the way heart rhythm disorders are treated.
The heart rhythm management market is evolving rapidly, driven by several key trends that are shaping the future of the field:
The future of heart rhythm management is bright, with innovative companies like AccurKardia, CAIRDAC, CardiaCare, EBAMed, and Volta Medical driving advancements in the field. With a growing global patient population and continued technological improvements, the heart rhythm management market is poised for continued growth. As the industry shifts toward less invasive, more personalized treatment options, these companies will be at the forefront of shaping the future of electrophysiology.
In the coming years, we expect to see even more groundbreaking innovations in heart rhythm management, further improving the quality of life for patients with arrhythmias and revolutionizing the way heart rhythm disorders are treated.
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy